Orchestra BioMed Holdings, Inc. has grown revenue 95% a year over three years and 112% a year over five. Revenue growth, 3-year annual rate: +95% (Biotechnology median +17%). Revenue growth, 5-year rate: +112%, growth has slowed since the five-year average. Years of annual history on file: 5, FY2021 to FY2025, as filed.

OBIOOrchestra BioMed Holdings, Inc.

Healthcare

$5.73+110% 1Y

$5.73

$2.8752 weeks$6.36

Is it growing?

Mixed

Neither accelerating nor breaking down: revenue growing +986% year on year, but operating margin narrowing (−8768.0 points).

1 good, 1 to watch, 1 without data

Revenue trend+986% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings.

Margin direction−8768.0 points operating

Trailing-twelve-month operating margin, -11952.8% now against -3184.8% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is OBIO growing?

Orchestra BioMed Holdings, Inc. has grown revenue 95% a year over three years and 112% a year over five.

+95%

Revenue growth, 3-year annual rate · Biotechnology median +17% · compounding fast · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +112%
Revenue growth, 5-year rate · +95% over three · growth has slowed since the five-year average
Years of annual history on file: 5
Years of annual history on file · FY2021 to FY2025, as filed

Details›